https://investors.niox.com/media/press-releases/ 2025-04-01T12:48:09+00:00 https://investors.niox.com/media/press-releases/circassias-extended-offer-period-for-aerocrine-has-increased-acceptances-to-97-2-percent/ 2020-07-21T13:16:28+00:00 https://investors.niox.com/media/press-releases/completion-of-acquisition-of-prosonix-limited/ 2020-07-21T13:16:28+00:00 https://investors.niox.com/media/press-releases/notice-of-interim-results/ 2020-07-21T13:16:29+00:00 https://investors.niox.com/media/press-releases/circassia-announces-duaklir-new-drug-application-nda-and-tudorza-supplemental-nda-accepted-for-review-by-fda/ 2020-07-21T13:40:51+00:00 https://investors.niox.com/media/press-releases/circassia-announces-submission-of-duaklir-new-drug-application-and-tudorza-supplemental-new-drug-application-in-the-united-states/ 2020-07-21T13:41:22+00:00 https://investors.niox.com/media/press-releases/circassia-announces-positive-data-presented-at-2018-american-thoracic-society-conference-from-tudorza-phase-iv-and-duaklir-phase-iii-studies/ 2020-07-21T13:42:10+00:00 https://investors.niox.com/media/press-releases/preliminary-results-for-the-year-ended-31-december-2017/ 2020-07-21T13:42:42+00:00 https://investors.niox.com/media/press-releases/circassia-receives-innovative-technology-contract-from-vizient-inc-for-niox-vero-asthma-management-products/ 2020-07-21T13:43:13+00:00 https://investors.niox.com/media/press-releases/circassia-announces-tudorza-successfully-met-both-primary-endpoints-in-ascent-phase-iv-study-in-chronic-obstructive-pulmonary-disease/ 2020-07-21T13:43:40+00:00 https://investors.niox.com/media/press-releases/circassia-welcomes-new-nice-guidelines-recommending-use-of-feno-testing-in-asthma-diagnosis/ 2020-07-21T13:44:14+00:00 https://investors.niox.com/media/press-releases/interim-results-for-the-six-months-ended-30-june-2017/ 2020-07-21T13:44:46+00:00 https://investors.niox.com/media/press-releases/circassia-announces-european-launch-of-niox-vero-nasal-mode-for-screening-of-primary-ciliary-dyskinesia/ 2020-07-21T13:45:54+00:00 https://investors.niox.com/media/press-releases/circassia-announces-duaklir-successfully-met-primary-endpoints-in-amplify-phase-iii-study-in-chronic-obstructive-pulmonary-disease/ 2020-07-21T13:46:19+00:00 https://investors.niox.com/media/press-releases/preliminary-results-for-the-year-ended-31-december-2016/ 2020-07-21T13:46:50+00:00 https://investors.niox.com/media/press-releases/circassia-announces-top-line-results-from-house-dust-mite-allergy-field-study/ 2020-07-21T13:47:28+00:00 https://investors.niox.com/media/press-releases/completion-of-the-transaction-and-admission-to-trading-on-the-london-stock-exchange/ 2020-07-21T13:49:08+00:00 https://investors.niox.com/media/press-releases/proposed-collaboration-and-securing-of-certain-u-s-commercial-rights-to-tudorza-and-duaklir-from-astrazeneca/ 2020-07-21T13:49:49+00:00 https://investors.niox.com/media/press-releases/interim-results-for-the-six-months-ended-30-june-2016/ 2020-07-21T13:50:49+00:00 https://investors.niox.com/media/press-releases/circassia-announces-top-line-results-from-cat-allergy-phase-iii-study/ 2020-07-21T13:51:47+00:00 https://investors.niox.com/media/press-releases/preliminary-results-for-the-year-ended-31-december-2015/ 2020-07-21T13:54:10+00:00 https://investors.niox.com/media/press-releases/circassia-announces-positive-outcome-of-european-decentralised-procedure-for-approval-of-its-fluticasone-propionate-equivalent-of-gsks-flixotide-pmdi/ 2020-07-21T13:54:34+00:00 https://investors.niox.com/media/press-releases/circassia-business-update/ 2020-07-21T13:55:11+00:00 https://investors.niox.com/media/press-releases/interim-results-for-the-six-months-ended-30-june-2015/ 2020-07-21T13:55:57+00:00 https://investors.niox.com/media/press-releases/proposed-acquisitions-of-aerocrine-ab-and-prosonix-limited-creating-a-world-class-allergy-and-asthma-specialty-pharma-business/ 2020-07-21T13:58:09+00:00 https://investors.niox.com/media/press-releases/preliminary-results-for-the-year-ended-31-december-2014/ 2020-07-21T14:02:51+00:00 https://investors.niox.com/media/press-releases/circassia-interim-management-statement/ 2020-07-21T14:05:18+00:00 https://investors.niox.com/media/press-releases/interim-results-for-the-six-months-ended-30-june-2014/ 2020-07-21T14:06:11+00:00 https://investors.niox.com/media/press-releases/circassia-announces-results-from-house-dust-mite-allergy-treatment-phase-iib-two-year-follow-up-study/ 2020-07-21T14:06:30+00:00 https://investors.niox.com/media/press-releases/interim-management-statement/ 2020-07-21T14:07:12+00:00 https://investors.niox.com/media/press-releases/circassia-to-exercise-option-for-full-us-commercial-rights-to-copd-treatment-tudorza-from-astrazeneca/ 2020-07-27T13:54:33+00:00 https://investors.niox.com/media/press-releases/interim-results-for-the-six-months-ended-30-june-2018/ 2020-07-27T13:54:39+00:00 https://investors.niox.com/media/press-releases/circassia-group-plc-preliminary-results-for-the-year-ended-31-december-2019-2/ 2020-09-24T15:22:53+00:00 https://investors.niox.com/media/press-releases/circassia-group-plc-preliminary-results-for-the-year-ended-31-december-2019-2-2/ 2021-03-24T07:27:16+00:00 https://investors.niox.com/media/press-releases/circassia-group-plc-preliminary-results-for-the-year-ended-31-december-2019-2-2-2/ 2022-03-24T10:00:14+00:00 https://investors.niox.com/media/press-releases/circassia-group-plc-preliminary-results-for-the-year-ended-31-december-2019-2-2-2-2/ 2022-03-24T10:04:18+00:00 https://investors.niox.com/media/press-releases/circassia-group-plc-preliminary-results-for-the-year-ended-31-december-2019-2-2-2-2-2/ 2022-09-14T10:57:14+00:00 https://investors.investors.niox.com/wp-content/uploads/2019/12/Ian-Johnson-web.jpg https://investors.investors.niox.com/wp-content/uploads/2022/09/CIR-PR-XX_Interim-Results-2022-FINAL_Page_01-211x300.jpg https://investors.niox.com/media/press-releases/niox-group-plc-final-results-2023/ 2024-03-27T09:15:50+00:00 https://investors.investors.niox.com/wp-content/uploads/2019/12/Ian-Johnson-web.jpg https://investors.niox.com/media/press-releases/circassia-group-plc-preliminary-results-for-the-year-ended-31-december-2019-2-2-2-2-3/ 2024-03-27T09:16:06+00:00 https://investors.investors.niox.com/wp-content/uploads/2019/12/Ian-Johnson-web.jpg https://investors.niox.com/media/press-releases/circassia-group-plc-preliminary-results-for-the-year-ended-31-december-2019-2-2-2-2-2-2/ 2024-03-27T09:16:32+00:00 https://investors.niox.com/media/press-releases/interim-results-for-the-six-months-ended-30-june-2024/ 2024-09-26T13:07:04+00:00 https://investors.niox.com/wp-content/uploads/2019/12/Ian-Johnson-web.jpg https://investors.niox.com/media/press-releases/circassia-group-plc-preliminary-results-for-the-year-ended-31-december-2019/ 2025-01-07T17:08:46+00:00 https://investors.niox.com/media/press-releases/proposed-transfer-of-assets-april-2020/ 2025-01-07T17:08:57+00:00 https://investors.niox.com/media/press-releases/circassia-announces-business-update-2/ 2025-01-07T17:09:02+00:00 https://investors.niox.com/media/press-releases/update-on-circassias-licensing-agreement-with-beyondair-inc-for-lungfit-ph/ 2025-01-07T17:09:07+00:00 https://investors.niox.com/media/press-releases/circassia-announces-board-changes/ 2025-01-07T17:09:12+00:00 https://investors.niox.com/media/press-releases/circassia-announces-duaklir-us-launch-at-american-college-of-chest-physicians-chest-annual-meeting-2019/ 2025-01-07T17:09:16+00:00 https://investors.niox.com/media/press-releases/interim-results-for-the-six-months-ended-30-june-2019/ 2025-01-07T17:09:20+00:00 https://investors.niox.com/media/press-releases/circassia-appoints-industry-veteran-jonathan-emms-as-chief-operating-officer/ 2025-01-07T17:09:27+00:00 https://investors.niox.com/media/press-releases/circassia-announces-publication-of-tudorza-phase-iv-ascent-study-in-the-journal-of-the-american-medical-association/ 2025-01-07T17:09:31+00:00 https://investors.niox.com/media/press-releases/preliminary-results-for-the-year-ended-31-december-2018/ 2025-01-07T17:10:02+00:00 https://investors.niox.com/media/press-releases/circassia-announces-fda-approval-of-duaklir-for-maintenance-treatment-of-chronic-obstructive-pulmonary-disease/ 2025-01-07T17:10:07+00:00 https://investors.niox.com/media/press-releases/circassia-announces-fda-approval-of-tudorza-supplemental-new-drug-application/ 2025-01-07T17:10:11+00:00 https://investors.niox.com/media/press-releases/admission-to-aim/ 2025-01-07T17:10:14+00:00 https://investors.niox.com/media/press-releases/admission-to-trading-on-the-london-stock-exchange/ 2025-01-07T17:11:50+00:00 https://investors.niox.com/media/press-releases/niox-group-plc-final-results-2023-2/ 2025-04-01T12:48:09+00:00